Aurora Cannabis ( (TSE:ACB) ) just unveiled an announcement.
Aurora Cannabis has announced a groundbreaking discovery of a genetic resistance to powdery mildew, a significant pathogen in cannabis cultivation. This development, achieved at their Aurora Coast research facility, is expected to lead to the creation of mildew-resistant cannabis cultivars, enhancing biosecurity, reducing production costs, and improving product quality. The discovery, protected by international patents, positions Aurora as a leader in cannabis science, potentially opening new market opportunities and advancing cultivation methods globally.
More about Aurora Cannabis
Aurora Cannabis Inc. is a leading global medical cannabis company based in Edmonton, Alberta, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand. The company is known for its pioneering efforts in the cannabis industry, offering a diverse portfolio of brands for adult-use and medical cannabis. Aurora is driven by science and innovation, focusing on high-quality cannabis products and holding a controlling interest in Bevo Farms Ltd., a major supplier of propagated agricultural plants in North America.
YTD Price Performance: -3.56%
Average Trading Volume: 2,932,321
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $236.6M
For a thorough assessment of ACB stock, go to TipRanks’ Stock Analysis page.